
Agenta Biotechnologies Inc (AKA: Monoclonal Partnerships International) Profile last edited on: 12/26/22
CAGE: 47XP1
UEI: ----------
Business Identifier: Implantable devices for improving the healing and repair process Is this YOUR Company?
Ensure accuracy and completeness of YOUR Company Profile by completing the brief Survey Instrument attached
Do you know about this Awardees?
Let us encourage you to provide any data which would enhance the completeness of this firm's profile.
Location Information
1500 1st Avenue N Suite L105 Unit 31
Birmingham, AL 35203
Birmingham, AL 35203
Location: Single
Congr. District: 07
County: Jefferson
Congr. District: 07
County: Jefferson
Public Profile
Agenta Biotechnologies Inc is discovery-based biotechnology corporation developing implantable devices (e.g. membranes, sponges, or micro-particles) to stimulate and improve the healing and repair process. The technology enables localized proteoglycan expression with or without growth factors to in order to promote healing, provide structure and to increase both blood supply as well as tissue hydration. These therapeutics can be applied to bone, cartilage, ligaments, discs in the spine, and skin, or serve as coatings for vascular stents and implants. This technology will lead to improvements in spine and vertebral disc treatments, better skin healing after burn wounds, healing of sores that wonât respond to current therapies in diabetic patients or in the elderly and repair of damaged skin from sun or age. The firmâs work has produced technologies that create both near-term commercial operations and high-value long-term development opportunities. These technologies include a patented synthetic bone graft with published superiority to leading competitors; a strong, pliable, yet dissolvable, surgical barrier membrane made from a specialized sugar in a patented manner for application to bone, cartilage, ligament, skin and wound healing, breast reconstruction and hernia repair. The membrane also serves as a delivery device to allow slow-release drugs to be resorbed; and a new, patented skin substitute for the healing of large skin ulcers or chronic ulcers of the foot and leg associated with diabetes and a
Extent of SBIR involvement
Synopsis: Awardee Business Condition
Employee Range
5-9Revenue Range
.5M-1MVC funded?
NoPublic/Private
Privately HeldStock Info
----IP Holdings
5-9Awards Distribution by Agency
Most Recent SBIR Projects
Year | Phase | Agency | Total Amount | |
---|---|---|---|---|
2011 | 1 | NIH | $157,069 | |
Project Title: Dna Pro-Drug Technology In Localized Wound Healing And Tissue Regeneration | ||||
2010 | 2 | NIH | $1,181,518 | |
Project Title: Molecular Heparan Sulfate Delivery in Guided Tissue Regeneration | ||||
2010 | 1 | NIH | $156,792 | |
Project Title: Nucleic Acid Delivery Of Growth Factors And Heparan Sulfate Proteoglycans For Enh | ||||
2008 | 2 | NIH | $998,307 | |
Project Title: Molecular Heparan Sulfate Delivery in Wound Regeneration | ||||
2006 | 1 | NIH | $121,980 | |
Project Title: Molecular Probes for Platelet Heparanase-Digested |
Key People / Management
Arthur A DeCarlo -- President & Chief Science Officer
Maria Belousova -- Research Scientist
Thomas Dooley -- Vice President of Research and Development
April L Ellis -- Dermatology Program Director
Hernan Grenett -- Director of Vascular Stent Program
Patrick Hardigan -- Research Scientist
Chuanyu Li -- Research Scientist
Don Petersen -- Research Scientist
John Whitelock -- Research Scientist
Maria Belousova -- Research Scientist
Thomas Dooley -- Vice President of Research and Development
April L Ellis -- Dermatology Program Director
Hernan Grenett -- Director of Vascular Stent Program
Patrick Hardigan -- Research Scientist
Chuanyu Li -- Research Scientist
Don Petersen -- Research Scientist
John Whitelock -- Research Scientist
Company News
Aug
24
2012
|
Entrepreneur Spotlight - Magenta Medical Inc |